Actemra Looks Promising in Scleroderma
Encouraging results were seen for tocilizumab (Actemra) in the treatment of diffuse systemic sclerosis (SSc) in a proof-of-concept study by Christopher P. Denton, MBBS, of University College Londo.
At 24 weeks, a numerically favorable response was seen on modified Rodnan skin scores and lung fibrosis among patients randomized to tocilizumab compared with those receiving placebo. The study is now continuing with a phase III trial that includes a greater number of patients.
news & events
Focus on your wellbeing
Find the right tools to help you focus on your wellbeing.
Influenza vaccination or not?
The northern hemisphere is entering autumn and winter and so is the seasonal influenza.
Participate in online survey
Do you have diffuse scleroderma? Your help is needed in this survey.